<DOC>
	<DOCNO>NCT01618214</DOCNO>
	<brief_summary>This trial conduct Asia . The aim trial compare BIAsp 30 twice daily individually adjust subject versus BIAsp 30 twice daily individually adjust investigator combine oral antidiabetic drug ( OADs ) subject type 2 diabetes inadequately control premixed human insulin . Subjects continue OAD background treatment : Metformin plus/minus alpha-glucosidase inhibitor .</brief_summary>
	<brief_title>Comparison Subject-driven Titration Biphasic Insulin Aspart ( BIAsp ) 30 Twice Daily Versus Investigator-driven Titration BIAsp 30 Twice Daily Both Combination With Oral Antidiabetic Drugs Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin aspart , insulin aspart protamine drug combination 30:70</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Biphasic Insulins</mesh_term>
	<mesh_term>Hypoglycemic Agents</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<mesh_term>Insulin , Isophane</mesh_term>
	<criteria>Informed consent obtain trialrelated activity . Trialrelated activity procedure carry part trial , include activity determine suitability trial Type 2 diabetes mellitus ( diagnose clinically ) least 12 month Currently treat premixed/selfmixed human insulin ( proportion shortacting insulin equal low 30 % ) BID ( twice daily ) combine metformin without alphaglucosidase inhibitor least 3 month prior screen visit ( Visit 1 ) minimum dose state : Metformin : least 1500 mg/day maximum tolerate dose least 1000 mg/day ( unchanged dosing within 3 month prior Visit 1 ) OR alphaglucosidase inhibitor : acarbose miglitol least 150 mg/day , voglibose least 0.6 mg/day Total daily insulin dose 1.4 IU/Kg HbA1c equal 7.0 % equal 9.5 % ( central laboratory ) Body Mass Index ( BMI ) equal 35.0 kg/m^2 Treatment insulin secretagogue , thiazolidinedione ( TZD ) , dipeptidyl peptidase4 ( DPP4 ) inhibitor Glucagonlike peptide1 ( GLP1 ) receptor agonist within last 3 month prior Visit 1 Previous use insulin intensification treatment ( premixed insulin thrice daily , basal bolus regimen , continuous subcutaneous insulin infusion ( CSII ) ) 14 day Previous use insulin premixed/selfmixed human insulin ( proportion short act insulin equal low 30 % ) BID within 3 month prior Visit 1 Recurrent severe hypoglycaemia ( 1 severe hypoglycaemic episode , last 12 month ) hypoglycaemic unawareness judge investigator hospitalisation diabetic ketoacidosis previous 6 month Known proliferative retinopathy maculopathy require treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>